Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSTR2-sNIR probe (also known as TATE-sNIR) is a near-infrared (NIR) fluorescent imaging probe developed for precision fluorescence-guided surgery, particularly for the intraoperative visualization of meningiomas and other somatostatin receptor type 2 (SSTR2)-expressing tumors. The probe is synthesized by conjugating the somatostatin analogue TATE (Tyr3-octreotate) to sNIR, a novel cyanine dye that exhibits superior photostability, faster clearance, and reduced non-specific background retention compared to standard dyes like IRDye800. By specifically binding to SSTR2, which is highly overexpressed in meningiomas, SSTR2-sNIR enables real-time, high-contrast visualization of microscopic tumor remnants at the resection bed, potentially reducing the risk of tumor recurrence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TATE-sNIR.